Invention Grant
- Patent Title: Anti-CD25 antibody agents
-
Application No.: US16352709Application Date: 2019-03-13
-
Publication No.: US10752691B2Publication Date: 2020-08-25
- Inventor: Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
- Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- Applicant Address: GB London GB Hertfordshire
- Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee Address: GB London GB Hertfordshire
- Agency: Choate Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Michael L. Vetter
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6e8359c2 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@1f531293 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@41da006f com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@49378bfb
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61P35/00 ; A61K39/00 ; C12N15/85 ; A61P35/02 ; C07K14/55
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
Public/Granted literature
- US20190300613A1 ANTI-CD25 ANTIBODY AGENTS Public/Granted day:2019-10-03
Information query
